Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting

Xilio Therapeutics Announces Closing of Initial Public Offering

Xilio Therapeutics Announces Pricing of Initial Public Offering

Xilio Therapeutics Announces FDA Clearance of Investigational New Drug Application for XTX202 for the Treatment of Solid Tumors

Xilio Therapeutics Appoints Timothy D. Hunt as Chief Culture and Corporate Affairs Officer

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX101 for the Treatment of Patients with Solid Tumors

Xilio Therapeutics Appoints Sara Bonstein to Its Board of Directors

Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors

Xilio Therapeutics Announces Clinical Trial Collaboration With Merck on Anti-CTLA-4 Monoclonal Antibody Program

Xilio Therapeutics to Present Preclinical Data Highlighting Anti-Tumor Activity and Tolerability of XTX202 at the 2021 ASCO Annual Meeting